Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.
EMBO Mol Med. 2019 Jul;11(7):e9982. doi: 10.15252/emmm.201809982. Epub 2019 May 24.
EMBO Mol Med. 2019.
PMID: 31273933
Free PMC article.
BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors.
Reisländer T, Lombardi EP, Groelly FJ, Miar A, Porru M, Di Vito S, Wright B, Lockstone H, Biroccio A, Harris A, Londoño-Vallejo A, Tarsounas M.
Reisländer T, et al.
Nat Commun. 2019 Jul 17;10(1):3143. doi: 10.1038/s41467-019-11048-5.
Nat Commun. 2019.
PMID: 31316060
Free PMC article.
Item in Clipboard
DNA Damage and Cancer Immunotherapy: A STING in the Tale.
Reisländer T, Groelly FJ, Tarsounas M.
Reisländer T, et al.
Mol Cell. 2020 Oct 1;80(1):21-28. doi: 10.1016/j.molcel.2020.07.026. Epub 2020 Aug 17.
Mol Cell. 2020.
PMID: 32810436
Free article.
Review.
Item in Clipboard
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents.
Herter S, Morra L, Schlenker R, Sulcova J, Fahrni L, Waldhauer I, Lehmann S, Reisländer T, Agarkova I, Kelm JM, Klein C, Umana P, Bacac M.
Herter S, et al. Among authors: reislander t.
Cancer Immunol Immunother. 2017 Jan;66(1):129-140. doi: 10.1007/s00262-016-1927-1. Epub 2016 Nov 17.
Cancer Immunol Immunother. 2017.
PMID: 27858101
Free PMC article.
Item in Clipboard
Unresectable biliary tract cancer: Current and future systemic therapy.
Zhang D, Dorman K, Westphalen CB, Haas M, Ormanns S, Neumann J, Seidensticker M, Ricke J, De Toni EN, Klauschen F, Algül H, Reisländer T, Boeck S, Heinemann V.
Zhang D, et al. Among authors: reislander t.
Eur J Cancer. 2024 May;203:114046. doi: 10.1016/j.ejca.2024.114046. Epub 2024 Apr 12.
Eur J Cancer. 2024.
PMID: 38626513
Free article.
Review.
Item in Clipboard
Long-Term Progression-Free Survival of a Pre-Treated Patient with Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil.
Michl GM, Vogt FM, Nouriani A, Ladurner R, Kremer M, Reisländer T, Michl M.
Michl GM, et al. Among authors: reislander t.
Chemotherapy. 2024;69(1):27-34. doi: 10.1159/000531525. Epub 2023 Jun 19.
Chemotherapy. 2024.
PMID: 37336201
Free PMC article.
Item in Clipboard
Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
Kröning H, Göhler T, Decker T, Grundeis M, Kojouharoff G, Lipke J, Semsek D, Moorahrend E, Sauer A, Bruch HR, Liersch R, Nusch A, Vehling-Kaiser U, Welslau M, Grunewald R, Harich HD, Stephany M, Uhlig J, de Buhr R, Frank M, Hogrefe C, Marschner N, Potthoff K, Hartmann F, Reisländer T, Schwaner I.
Kröning H, et al. Among authors: reislander t.
Int J Cancer. 2023 Sep 15;153(6):1227-1240. doi: 10.1002/ijc.34603. Epub 2023 Jun 1.
Int J Cancer. 2023.
PMID: 37260368
Item in Clipboard
Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial.
Weiss L, Karthaus M, Riera-Knorrenschild J, Kretzschmar A, Welslau M, Vehling-Kaiser U, Pelz H, Ettrich TJ, Hess J, Reisländer T, Klein A, Heinemann V; TALLISUR study group.
Weiss L, et al. Among authors: reislander t.
ESMO Open. 2022 Feb;7(1):100391. doi: 10.1016/j.esmoop.2022.100391. Epub 2022 Feb 8.
ESMO Open. 2022.
PMID: 35149429
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite